Overall, the expert HCPs participating in the Delphi Survey expressed considerable confidence that primary care teams will adapt to managing insulin‐treated people with T2D using CGM (71.4%) and that this will reduce diabetes‐related healthcare costs for this participant group (94.3%). This evidence concerns the gene INS and diabetes mellitus.